Study of JNJ-78934804 (guselkumab and golimumab) versus guselkumab in adults with moderately to severely active Crohn’s disease
- Substances:GolimumabGuselkumab
Austria- Participants:18–64 years · 65+ years
- Substances:Golimumab
Rare diseases
Investigational molecules
Locations
AustriaEfficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis
AustriaDiscontinuation of methotrexate (drug combination) in rheumatoid arthritis patients using TNF inhibitors
The NetherlandsStudy on Treatment Strategies for Children and Adolescents with Juvenile Idiopathic Arthritis Using Methotrexate and Drug Combination
NorwayStudy on Reducing Immunosuppressive Drugs in Adults with Psoriatic Arthritis: Methotrexate Disodium, Abatacept, and Certolizumab Pegol
GermanyStudy Comparing Methotrexate or Leflunomide with Targeted Therapy vs. Methotrexate or Leflunomide with Drug Combination for Rheumatoid Arthritis Patients
FranceStudy on Early Drug Withdrawal in Children with Juvenile Idiopathic Arthritis Using Secukinumab and Drug Combination for Those in Clinical Remission
BelgiumAdd‑on Unsaturated Fatty Acids with TNF‑Alpha Inhibitor Drug Combination in Patients with Psoriatic Arthritis
ItalyMethotrexate tapering versus usual care in elderly (≥70) patients with rheumatoid arthritis in low disease activity – drug combination study
DenmarkMaintenance versus tapered TNF‑alpha inhibitor therapy (golimumab, etanercept, adalimumab) in children and adolescents with juvenile idiopathic arthritis
NorwayStudy on the Effects of Adalimumab, Vedolizumab, and Tofacitinib on Heart Health in Patients with Ulcerative Colitis
FranceStudy on the Effects of Tofacitinib and Drug Combination on Blood Clotting in Patients with Ulcerative Colitis
SpainTell us about your condition – we search every trial in Europe and connect you with the right site.